Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)
ID: 353483Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353483

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-198.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)." This initiative aims to explore the cellular and molecular mechanisms that affect the blood-brain barrier during passive anti-beta-amyloid immunotherapy, particularly in the context of Alzheimer's disease and related dementias. The program is significant for advancing the understanding of ARIA, which is crucial for improving the safety and efficacy of Alzheimer's therapeutics. Eligible applicants include various academic institutions, nonprofits, and state and local governments, with a funding ceiling of $500,000 per project per year, totaling up to $3.75 million annually for up to five projects. Interested parties must submit their applications by November 5, 2024, and can direct inquiries to grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-24-198.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-198-Full-Announcement.html
    PAR-24-198.html
    The Department of Health and Human Services has issued a funding opportunity aimed at exploring protective strategies to mitigate Amyloid-Related Imaging Abnormalities (ARIA) resulting from passive anti-beta-amyloid immunotherapy. This initiative, managed by the National Institutes of Health, specifically the National Institutes of Neurological Disorders and Stroke and the National Institute on Aging, seeks to uncover the cellular and molecular mechanisms impacting the blood-brain barrier during treatment for Alzheimer's disease and related dementias. Applications are welcomed for studies that leverage animal models to investigate the negative effects of this immunotherapy, particularly in relation to risk factors like age and APOE4 carrier status. Funding totals up to $3.75 million annually for up to five awarded projects, with each project limited to direct costs of $500,000 per year. Eligibility is extended to various academic institutions, nonprofits, and state and local governments, although foreign organizations are excluded. The submission process requires adherence to strict application guidelines and will not accept projects involving clinical trials. By fostering a better understanding of ARIA, the initiative aims to enhance the efficacy and safety of Alzheimer's therapeutics while addressing significant barriers in the field of Alzheimer's research.
    Similar Opportunities
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for clinical trials focused on the safety and efficacy of amyloid-beta directed antibody therapies in individuals with mild cognitive impairment and dementia associated with Lewy Body Dementia (LBD). This initiative aims to conduct Phase 2 placebo-controlled trials targeting mixed-etiology dementia populations, emphasizing the inclusion of diverse participants to ensure representative outcomes. The NIH plans to allocate up to $10 million for this project, which requires proposals to address relevant biomarkers and clinical diagnoses while incorporating community engagement strategies throughout the research process. Interested applicants can find more information and application details at the NIH grants website, with a submission deadline of January 24, 2025.
    Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)" aimed at investigating the interactions between COVID-19 and Alzheimer’s Disease-Related Dementias (ADRD). This initiative seeks research proposals that utilize animal, cell culture, or human tissue models to explore the mechanisms by which COVID-19 affects CNS pathology and cognitive outcomes, particularly in the context of existing AD/ADRD conditions. The NIH plans to allocate up to $3.75 million to support up to five awards, with individual budgets capped at $500,000 in direct costs per year. Interested applicants must submit their proposals by October 4, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" grant, aimed at developing interventions to prevent or treat cognitive and behavioral changes associated with Alzheimer's disease (AD) and related dementias (ADRD). The funding opportunity seeks to support both pharmacological and non-pharmacological clinical trials, with a focus on enhancing trial design and methodologies to address the growing public health crisis posed by these conditions, which currently affect over 6 million Americans. The total funding allocation for fiscal year 2025 is approximately $20 million, with applications due by October 17, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings," aimed at enhancing the understanding of Alzheimer’s Disease Related Dementias (ADRD). This initiative focuses on utilizing structural biology methodologies to investigate the relationships between protein structures and clinical outcomes of ADRD, specifically seeking to generate structural information on proteins implicated in the disease within their native cellular environments. The NIH plans to allocate up to $3 million annually for up to four grants, with each grant not exceeding $500,000 per year for a maximum of five years, contingent upon funding availability. Interested applicants can submit their proposals starting September 4, 2024, with a submission deadline of October 5, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)." This initiative aims to support research that establishes clinical trial readiness for community-driven interventions addressing barriers to health equity in Alzheimer's Disease Related Dementias (ADRD) among populations experiencing health disparities. Successful applications must include a Community Engaged Research Inclusion (CERI) Plan and a Plan for Enhancing Diverse Perspectives (PEDP), focusing on social determinants of health and the unique challenges faced by diverse communities. NIH plans to allocate approximately $2.25 million to fund three awards, with each project eligible for a maximum budget of $500,000 per year for up to four years. Applications are due by October 4, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.